Renal events and peripheral neuropathy reported with momelotinib in myelofibrosis: an indication-restricted FAERS study
This FAERS study indicates that momelotinib is disproportionately associated with reports of renal dysfunction and peripheral neuropathy in myelofibrosis patients compared to other JAK inhibitors, supporting the need for focused clinical monitoring despite the inability to establish causality.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Medicine often works by finding a way to calm an overactive immune system, but in doing so, it can sometimes create new problems elsewhere in the body. This is particularly true for a group of drugs used to treat myelofibrosis, a serious condition where the bone marrow becomes scarred and unable to produce healthy blood cells. Doctors prescribe these medications to shrink an enlarged spleen and ease the fatigue and discomfort that come with the disease. However, as these treatments become more common, researchers must keep a close watch for unexpected side effects. Two specific concerns have recently emerged: damage to the kidneys and a tingling or numb sensation in the hands and feet known as peripheral neuropathy. While clinical trials provide a controlled view of how drugs work, they cannot capture every rare or delayed reaction that occurs when millions of people use a medication in the real world. To fill this gap, scientists turn to massive databases where doctors and patients report what happens after a drug is approved, looking for patterns that might signal a need for closer attention.
In a recent study, researchers examined a vast collection of safety reports to see if a specific drug called momelotinib was linked to these two issues more often than other similar treatments. They focused their search on reports received between late 2023 and mid-2026, looking only at cases where the drug was prescribed specifically for myelofibrosis. To make a fair comparison, they looked at reports for momelotinib alongside reports for three other drugs used for the same condition: ruxolitinib, fedratinib, and pacritinib. The team did not try to calculate how many people developed these problems, because the database does not track how many people took the medicine overall. Instead, they looked for "signals," which are simply instances where a specific side effect appears in the reports for one drug much more frequently than for the others, suggesting that something worth investigating might be happening.
The analysis revealed that reports of kidney problems and nerve damage were indeed much more common for momelotinib than for the other drugs in the group. When the researchers looked at the raw numbers, they found that for every report of kidney trouble with the other drugs, there were more than five such reports for momelotinib. Similarly, reports of nerve damage were nearly five times more frequent with momelotinib. These differences were so large that they were unlikely to be due to random chance. However, the researchers knew that the people reporting these events might not be the same across all drugs. For instance, doctors in the United States were far more likely to submit reports for momelotinib than for the other medications, and doctors tend to report more serious events than patients do. When the researchers adjusted their calculations to account for who was reporting and where the reports came from, the signal for kidney problems became weaker, though it remained noticeable. The signal for nerve damage, however, stayed strong even after these adjustments, suggesting that the link between momelotinib and nerve issues is particularly robust.
The study also looked at the details of the reports to understand the nature of these events. For kidney issues, the most common descriptions were general terms like "renal impairment" or "acute kidney injury," often appearing shortly after treatment began. For nerve problems, the reports frequently described "peripheral neuropathy," a condition where the nerves in the extremities malfunction. Interestingly, the researchers found that while both issues were reported more often with momelotinib, they rarely appeared together in the same patient report. This suggests that the two problems might be separate concerns rather than parts of a single syndrome. The data also showed that when comparing momelotinib to just one of the other drugs, fedratinib, the difference was not clear, likely because there were far fewer reports for fedratinib to compare against. This highlights that the findings are specific to how momelotinib compares to the group as a whole, rather than a universal rule that applies to every single alternative drug.
Ultimately, this research does not prove that momelotinib causes kidney failure or nerve damage, nor does it tell doctors how many patients will experience these effects. The database used for the study relies on voluntary reports, which can be influenced by how much attention a drug is receiving or how well doctors know to look for specific symptoms. What the study does provide is a clear warning sign that these two issues are being reported disproportionately with momelotinib compared to its peers. The findings suggest that doctors should monitor patients carefully for changes in kidney function and signs of nerve trouble, especially since the risk for nerve damage appears to persist even when accounting for reporting habits. The study concludes that while these signals are strong enough to warrant focused clinical follow-up, they are not yet a reason to change how the drug is prescribed, but rather a call to watch more closely and gather more precise data in the future.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.